Instil Bio News

News

Ticker

TIL

ISIN

US45783C2008

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Instil Bio Eulerpool News

Instil Bio Stock News

Instil Bio is being monitored by journalists and investors worldwide. We gather the latest Instil Bio news here.

January 7·
Benzinga
HC Wainwright & Co. Downgrades Instil Bio to Neutral
November 13·
Benzinga
Instil Bio Q3 Adj. EPS $(1.75) Beats $(2.35) Estimate
July 2·
Yahoo
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 2·
Benzinga
Instil Bio shares are trading higher after the company announced it received FDA Clearance for IND of AXN-2510.
July 2·
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
July 2·
Benzinga
Instil Bio Gets US FDA Clearance For IND Of AXN-2510, A PD-L1xVEGF Bispecific Antibody, With Phase 1 Solid Tumor Trial Set For 2025
June 20·
Yahoo
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
June 16·
Yahoo
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
June 11·
Yahoo
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
June 4·
Yahoo
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice
June 2·
Yahoo
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
May 30·
Yahoo
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
May 29·
Yahoo
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade
May 26·
SeekingAlpha
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
May 25·
SeekingAlpha
Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success
May 13·
Benzinga
Instil Bio Q1 Adj. EPS $(1.32) Beats $(2.59) Estimate
March 4·
Yahoo
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 2·
Yahoo
Jefferies Predicts Up to ~500% Jump for These 2 ‘Strong Buy’ Stocks
February 20·
Yahoo
Private equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as well
February 12·
SeekingAlpha
Invesco Main Street Small Cap Fund Q4 2024 Commentary

Instil Bio Stock Press Releases

Instil Bio regularly publishes news on the company's website that are relevant for investors.

August 12•
Instil Bio
Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
May 27•
Instil Bio
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
May 18•
Instil Bio
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)
May 16•
Instil Bio
Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
March 7•
Instil Bio
Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 2•
Instil Bio
Instil Bio to Present at the Cowen 42nd Annual Health Care Conference
November 15•
Instil Bio
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 8•
Instil Bio
Instil Bio to Present at Upcoming Investor Conferences in November
September 16•
Instil Bio
Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress
September 13•
Instil Bio
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
September 2•
Instil Bio
Instil Bio to Present at Upcoming Investor Conferences in September
August 12•
Instil Bio
Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
June 1•
Instil Bio
Instil Bio to Present at the Jefferies Virtual Healthcare Conference
May 13•
Instil Bio
Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
April 27•
Instil Bio
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
April 12•
Instil Bio
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting
March 23•
Instil Bio
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 18•
Instil Bio
Instil Bio Announces Pricing of Upsized Initial Public Offering

Instil Bio News 2026

This page contains all current news, analysis and press releases for Instil Bio stock (TIL, ISIN: US45783C2008). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Instil Bio.